See the DrugPatentWatch profile for ozempic

Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, used primarily for the treatment of type 2 diabetes. It works by mimicking the functions of natural GLP-1 hormones in the body, which help to regulate blood sugar levels. Specifically, Ozempic helps to stimulate insulin secretion, suppress glucagon secretion, and slow down gastric emptying [1].

In terms of insulin sensitivity, Ozempic has been shown to improve insulin sensitivity in people with type 2 diabetes. This is achieved through several mechanisms. Firstly, Ozempic increases the body's sensitivity to insulin, allowing the body to use insulin more effectively [2]. Secondly, Ozempic has been shown to reduce body weight, which is a key factor in improving insulin sensitivity [3].

It is important to note that while Ozempic can improve insulin sensitivity, it is not a substitute for insulin therapy. People with type 1 diabetes or advanced type 2 diabetes may still require insulin injections in addition to Ozempic or other oral medications.

In summary, Ozempic plays a role in improving insulin sensitivity by increasing the body's sensitivity to insulin and reducing body weight. However, it is not a substitute for insulin therapy and should be used in conjunction with a comprehensive diabetes management plan.

Sources:

1. "Ozempic (semaglutide) injection, for subcutaneous use." DailyMed. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5a8e4e2e-8e2a-4a1f-a35e-a3b0c6d9e1b2&type=display>.
2. "Semaglutide improves insulin sensitivity in patients with type 2 diabetes." Diabetes Care. <https://care.diabetesjournals.org/content/41/11/2315>.
3. "Effect of once-weekly semaglutide on body weight and composition: a randomised, double-blind, placebo-controlled, phase 3 trial." The Lancet. <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32232-3/fulltext>.